Strong SaaS Revenue and ARR Growth
SaaS revenue grew 17% year-over-year to CA$20.1M in Q3 (18% on a constant currency basis). SaaS ARR was CA$83.3M at quarter end, up 10% year-over-year (16% constant currency). Elite SaaS ARR (core product) grew 17% year-over-year (23% constant currency).
Record Adjusted EBITDA and Profitability Improvements
Adjusted EBITDA reached CA$5.0M in Q3, up 43% year-over-year and the highest adjusted EBITDA quarter in company history. Gross margin improved to 51% from 47% a year ago. Net profit was CA$1.7M (Q3 prior CA$1.2M) and EPS was CA$0.12 vs CA$0.08 a year ago. Year-to-date adjusted EBITDA increased to CA$13.3M from CA$9.1M (up ~46%).
Record Q3 SaaS Bookings and New-Logo Momentum
Company reported the largest Q3 SaaS bookings in its history, achieved without migration bookings. Bookings from new logos are up over 150% in the last 12 months versus the prior year period. Ending Q3 pipeline was up 30% year-over-year.
Strong YTD Revenue Growth and Balance Sheet Strength
For the first 9 months of FY'26, SaaS revenue was CA$58.9M (up 21% YoY), total revenue was CA$143.1M (up 10% YoY; 9% constant currency), and excluding hardware revenue grew 13% (12% CC). Cash and short-term investments were CA$36.2M and the company has no debt.
Market Traction in Healthcare and Pharmacy
Notable new logos include Memorial Sloan Kettering and UT Southwestern. Pharmacy pipeline grew more than 200% year-over-year. Pharmacy Summit registrations increased 77% YoY and participation from health system leaders rose 67% YoY, indicating strong brand and market engagement.
Commercial Launch of TecsysIQ and AI Momentum
TecsysIQ became commercially available in Q3, consolidating healthcare-specific external sources (ASHP, GUDID, FDA) with internal data to surface actionable insights. Management expects TecsysIQ to add baseline ARR (management cited ~CA$1M/yr as a baseline per year as it scales) and to act as an ARR accelerant by increasing platform stickiness.
Reaffirmed Guidance
Management reaffirmed full-year FY'26 guidance: SaaS revenue growth 20%-22%, total revenue growth 8%-10%, and adjusted EBITDA margin of 8%-9%.